Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Acta Neurol Belg
; 109(3): 238-42, 2009 Sep.
Article
em En
| MEDLINE
| ID: mdl-19902821
ABSTRACT
Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Glioblastoma
/
Antineoplásicos Alquilantes
/
Dacarbazina
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Acta Neurol Belg
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Holanda